Online Database of Chemicals from Around the World

(+)-(3aR,4R,5r,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one
[CAS# 53872-60-9]

List of Suppliers
Shenyang OllyChem Technology Co., Ltd. China Inquire  
+86 (24) 6225-9849
+86 13840042106
info@ollychem.com
oliverdu@ollychem.com
Chemical manufacturer since 2001
chemBlink standard supplier since 2007
Simagchem Corporation China Inquire  
+86 13806087780
sale@simagchem.com
Chemical manufacturer since 2002
chemBlink standard supplier since 2008
Taizhou Crene Biotechnology Co., Ltd. China Inquire  
+86 (576) 8881-3233
8820-5808
+86 13396860566
order@pharm-intermediates.com
QQ chat
Chemical manufacturer since 2011
chemBlink standard supplier since 2009
Zhejiang Ausun Pharmaceutical Co., Ltd. China Inquire  
+86 (576) 8558-9335
+86 13957690608
sales@ausunpharm.com
Chemical manufacturer since 2011
chemBlink standard supplier since 2009
Wilshire Technologies, Inc. USA Inquire  
+1 (609) 683-1117
Wilshire-info@evonik.com
Chemical manufacturer since 1997
chemBlink standard supplier since 2010
Intatrade Chemicals GmbH Germany Inquire  
+49 (3493) 605-465
sales@intatrade.de
Chemical distributor
chemBlink standard supplier since 2011
Changchun BC&HC Pharmaceutical Technology Co., Ltd. China Inquire  
+86 (431) 8087-1788
8087-1588
+86 15804318207
3468242165@qq.com
QQ chat
Chemical manufacturer since 2014
chemBlink standard supplier since 2016
Shanghai Yingrui Biopharm Co., Ltd. China Inquire  
+86 (21) 3358-5366
3466-6753
+86 13311639313
sales02@shyrchem.com
Skype Chat
QQ chat
Chemical manufacturer since 2009
chemBlink standard supplier since 2017
Complete supplier list of (+)-(3aR,4R,5r,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one
Identification
Classification Flavors and spices >> Synthetic spice >> Lactone and oxygen-containing heterocyclic compound >> Furan and pyran
Name (+)-(3aR,4R,5r,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one
Synonyms (3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one
Molecular Structure CAS # 53872-60-9, (+)-(3aR,4R,5r,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one, (3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one
Molecular Formula C18H19F3O5
Molecular Weight 372.34
CAS Registry Number 53872-60-9
EC Number 805-964-3
SMILES C1[C@H]([C@@H]([C@@H]2[C@H]1OC(=O)C2)/C=C/[C@H](COC3=CC=CC(=C3)C(F)(F)F)O)O
Safety Data
Hazard Symbols symbol symbol   GHS07;GHS08 Warning    Details
Hazard Statements H315-H319-H335-H361-H362    Details
Precautionary Statements P203-P260-P261-P263-P264-P264+P265-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P318-P319-P321-P332+P317-P337+P317-P362+P364-P403+P233-P405-P501    Details
Hazard Classification
up    Details
HazardClassCategory CodeHazard Statement
Eye irritationEye Irrit.2H319
Skin irritationSkin Irrit.2H315
Reproductive toxicityRepr.2H361
Reproductive toxicityLact.-H362
Specific target organ toxicity - single exposureSTOT SE3H335
SDS Available
up Discovory and Applicatios
(+)-(3aR,4R,5r,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one is a complex organic compound notable for its unique bicyclic structure and potential applications in medicinal chemistry. The discovery of this compound is rooted in the exploration of structurally diverse bicyclic molecules, which has attracted significant attention due to their potential biological activity and utility in drug development.

The molecular architecture of (+)-(3aR,4R,5r,6aS)-hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one features a hexahydrocyclopentafuran moiety that contributes to its rigidity and defines its three-dimensional conformation. The presence of hydroxyl and trifluoromethyl groups introduces polarity and enhances the compound's potential interactions with biological targets. These structural characteristics are significant in determining the compound's reactivity and pharmacological properties.

This compound has garnered attention due to its possible applications in treating conditions related to ocular health. Its structural similarity to known ophthalmic agents suggests that it may act as a potent modulator of intraocular pressure, making it a candidate for the management of glaucoma. Research into the pharmacological properties of this compound indicates that it may exhibit prostaglandin-like effects, which could be beneficial in the treatment of ocular hypertension.

Furthermore, the presence of the trifluoromethyl group enhances the compound's lipophilicity, facilitating its absorption and distribution within biological systems. This characteristic is particularly advantageous in drug development, where optimizing pharmacokinetics is crucial for the efficacy of therapeutic agents. Studies have indicated that compounds with similar structural features can effectively penetrate biological membranes, allowing for targeted action in specific tissues, such as the eye.

The potential applications of (+)-(3aR,4R,5r,6aS)-hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one extend beyond ophthalmology. Its unique structure and reactivity also make it a valuable intermediate in the synthesis of other biologically active compounds. The compound can participate in various chemical transformations, including nucleophilic substitutions and functional group modifications, contributing to the development of new drugs with enhanced therapeutic profiles.

In summary, (+)-(3aR,4R,5r,6aS)-hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one is a promising compound in the field of medicinal chemistry, with potential applications in treating ocular diseases and serving as an intermediate for further synthetic development. Ongoing research is focused on elucidating its full pharmacological profile and exploring its utility in various therapeutic contexts, underscoring its significance in advancing drug discovery and development.
Market Analysis Reports
List of Reports Available for (+)-(3aR,4R,5r,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-4-(3-trifluoromethyl)phenoxy-1-butenyl]-2H-cyclopenta[b]furan-2-one
Related Products
5-[(Hexahydro-4-hydroxy-1H-1,4-diazepin-1-yl)sulfonyl]isoquinoline  (2S,3aR,5S,6S,6aS)-Hexahydro-6-hydroxy-4,4-dimethyl-2,5-methano-2H-furo[3,2-b]pyrrolium bromide (1:1)  (4aS-cis)-4,4a,5,6,7,8-Hexahydro-8-hydroxy-4a,8-dimethyl-2(3H)-naphthalenone  (3R,3aR,7S,8aS)-3,3a,4,7,8,8a-Hexahydro-6-(2-hydroxyethyl)-3,7-dimethyl-2H-cyclohepta[b]furan-2-one  (3aS,4S,6aR)-Hexahydro-N-(6-hydroxyhexyl)-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide  Hexahydro-5-hydroxy-4-(hydroxymethyl)-2H-cyclopenta[b]furan-2-one  (3aS,4R,5S,6aR)-(+)-Hexahydro-5-hydroxy-4-(hydroxymethyl)-2H-cyclopenta[b]furan-2-one  (5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]pentanoic-2,2,3,3-d4 acid  (3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-1-octen-1-yl]-2H-cyclopenta[b]furan-2-one  (+)-(3aR,4R,5r,6aS)-Hexahydro-5-hydroxy-4-[(1E,3R)-3-hydroxy-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one  (2a,6a,8a,9ab)-Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one  (alphaS,1R,2R,3aS,9aS)-2,3,3a,4,9,9a-Hexahydro-2-hydroxy-5-methoxy-alpha-pentyl-1H-benz[f]indene-1-propanol  Hexahydro-6-(hydroxymethyl)-1H-1,4-diazepine-1-carboxylic acid 1,1-dimethylethyl ester  Hexahydro-5-(hydroxymethyl)-1H-1,4-diazepine-1-carboxylic acid 1,1-dimethylethyl ester  Hexahydro-3-(hydroxymethyl)-1H-1,4-diazepine-1-carboxylic acid 1,1-dimethylethyl ester  Hexahydro-4-(hydroxymethyl)-1,1-dimethyl-4-phenyl-1H-azepinium bromide  (4R,12aS)-3,4,6,8,12,12a-Hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid  (6aS,7R,13S,14R,16R)-6,6a,7,13,14,16-Hexahydro-16-(hydroxymethyl)-9-methoxy-8-(methoxymethoxy)-4,10,17-trimethyl-5-(2-propen-1-yloxy)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-14-carbonitrile  (2E,4E)-N-[(2S,5S)-1,2,3,4,5,6-Hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-3-oxo-1,4-benzodiazocin-8-yl]-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienamide  [3aR-(3aalpha,4alpha,5beta,6aalpha)]-Hexahydro-4-(hydroxymethyl)-5-(phenylmethoxy)-2H-cyclopenta[b]furan-2-one